Laplace Interventional Inc. Announces Series C Financing of $22M for its Transcatheter Tricuspid Valve Technology
The Series C financing was led by a global strategic investor along with participation from new investors Aphelion Cardeation and Unorthodox Ventures. Existing investors Engage Venture Partners, JWC Venture and Features Capital also participated in the round. Laplace Interventional plans to use the funds raised from this round towards completing their Early Feasibility Study (EFS) and work towards a pivotal study approval.
MINNEAPOLIS, March 16, 2025 /PRNewswire/ -- Minnesota based Laplace Interventional, a medical device company developing a transcatheter tricuspid valve technology, announced today that it has completed its Series C financing led by a non-disclosed global strategic investor along with investments from Aphelion Capital, Engage Venture Partners, Unorthodox Ventures, JWC Venture and Features Capital. The company also announced the addition of Ned Scheetz, Founding Managing Partner at Aphelion Capital to its Board of Directors.
Laplace Interventional's device aims to offer an improvement to the quality of life to patients worldwide diagnosed with Tricuspid Regurgitation (TR). Laplace Interventional is developing a prosthetic valve that is delivered through a minimally invasive procedure not requiring an open-heart surgery and thereby reducing future complications in patients.
'So far we have treated three patients in the Laplace EFS and all were discharged home within 1-2 days and are doing well. This was our first experience with a dedicated transcatheter tricuspid valve replacement platform and we are highly impressed with the intuitive deployment, imaging requirements, and overall ease of use of the Laplace system in a variety of challenging anatomies,' said Dr. Brandon Jones, Interventional Cardiologist and Medical Director of Structural Heart at Providence St. Vincent Medical Center, Portland, Oregon. Laplace has enrolled 22 patients in the United States largely as part of their US EFS Study (and 25 globally) with encouraging results.
'This round of financing marks a significant milestone for the company and further validates our progress over the past few years.' said Ramji Iyer, PhD, Founder and CEO of Laplace Interventional. 'We are grateful to our patients, physicians as well as new and existing investors for their continued support and look forward to working towards starting a pivotal trial.' Laplace Interventional plans to use the funds raised from this round towards completing their feasibility study (US EFS and OUS) and work towards a pivotal study.
'Aphelion Cardeation, a venture fund formed to invest in innovative health care products, services and technologies that align with the mission of the American Heart Association, is proud to participate in this round of financing,' said Ned Scheetz with Aphelion Capital. 'We are inspired by Laplace's innovative solution for TR and its potential to transform care for millions of patients worldwide.'
Caution: Laplace Interventional's device is in its development phase and is NOT approved or cleared by the FDA or any other regulatory body in any region of the world.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
29-05-2025
- Business Wire
Broadband Forum's New Spec Cracks the Code
FREMONT, Calif.--(BUSINESS WIRE)--Broadband service providers (BSPs) now have more visibility and control of devices and applications connected over a Thread network thanks to the publication of an updated specification from Broadband Forum. The latest update to its TR-181 data model – Device:2.19 – is set to provide comprehensive support for managed smart home deployments using low-power mesh networking. Those BSPs that adopt the Broadband Forum data model can remotely communicate and manage the Customer Premises Equipment (CPE), such as modems, routers, or wireless access points, and diagnose problems with Thread connected devices. 'Interoperability of devices is a hot topic in the smart home, and we recognize the importance of our role in bridging communications between all Thread connected devices,' Broadband Forum CEO Craig Thomas said. 'Alongside this, the updated specification promises improved management of diverse smart home technologies, such as Wi-Fi HaLow. We are excited to see the Connected User Work Area advance its mission to simplify the home broadband network.' Another major enhancement is a revamped data model for cellular radio interfaces, built to support FWA use cases. This advancement aligns with Broadband Forum's Wireless Wireline Convergence work, enables broadband CPE to leverage cellular connectivity more effectively, and aligns with deployment models using Broadband Forum's USP/TR-369 protocol for management, telemetry, and automation. Device:2.19 also expands support for Wi-Fi Alliance's Data Elements Release 4, introducing standardized KPIs that improve monitoring and troubleshooting of Wi-Fi performance. The inclusion of Wi-Fi HaLow elements further extends coverage to long-range, low-power devices. 'Device:2.19 reflects our commitment to evolving with network operator needs,' said Jason Walls of QA Cafe, Co-Director of Broadband Forum's Connected User Work Area. 'With support for next-generation smart home technology, Wi-Fi performance metrics, and Fixed Wireless Access, we're giving BSPs powerful tools to deliver exceptional broadband experiences.' The TR-181 Device:2.19 data model continues to apply broadly across residential gateways, CPE, and other access devices, supporting flexible deployment and lifecycle management under a unified, standards-based framework. About the Broadband Forum The Broadband Forum is an industry-driven global standards development organization helping operators, application providers, and vendors deliver better, services-led broadband. As the industry-recognized center of competence, the Broadband Forum provides an accessible, efficient, and effective community where all broadband stakeholders can collaborate on, develop, and promote open standards and open software. This provides the basis for deployable solutions for the global broadband industry. The forum publishes interoperable standards and open software, has launched certification programs, and promotes industry education. These best practices and models can be adopted to help realize an effective broadband ecosystem that drives a thriving, services-led broadband industry based on global collaboration, open standards, and open source, maximizing value for all stakeholders. For more information, visit For the latest updates, follow Broadband Forum on LinkedIn, Twitter, and YouTube.
The Hill
27-05-2025
- The Hill
5 ways the ‘Big, Beautiful Bill' could impact Americans
Congressional Republicans are moving quickly to pass a mammoth tax and spending cuts package that could have a direct impact on millions of Americans, and drastic consequences for the economy. The 1,000-plus page bill recently passed by the House would extend tax cuts set to expire as part of President Trump's signature 2017 tax law, provisions aimed at nixing taxes on tips and overtime pay. It also includes a host of reforms to programs like Medicaid and food stamps that early estimates project could reduce spending in those areas by hundreds of billions of dollars in the next decade. As Senate Republicans look to make their own changes to the package, here's five pieces of the House bill that could make waves across American life. The centerpiece of the House measure is an extension and expansion of Trump's 2017 tax cut law. The most significant part of the tax provisions may actually be the least noticeable: the cementing of current personal income tax rates. Rather than providing a big tax cut, the bill instead prevents a major increase in taxes that would have occurred next year. But the House bill also includes several new tax cuts that could boost take-home pay for Americans across a wide range of income levels and demographics. On the lower end of the income spectrum, the bill would increase the child tax credit, eliminate taxes on most tips and overtime pay, and provide a credit to cover the cost of taxes on Social Security benefits. The bill also includes a significantly higher cap on the state and local tax (SALT) deduction, which primarily benefits residents of high-income, high-tax cities and their suburbs. Much of the savings in the legislation comes from Medicaid. The bill would cut nearly $800 billion from the program through a combination of provisions including work requirements on 'able-bodied adults' through age 64 without dependents, a freeze on provider taxes, more frequent checks of people's eligibility, and reducing federal Medicaid payments to states that provide healthcare coverage for undocumented immigrants. The Congressional Budget Office estimated close to 10 million people would lose insurance coverage as a result. The Medicaid provision with arguably the most direct impact on beneficiary coverage would be the provision for anyone 'able bodied' between the ages of 19 and 64 to work, go to school or volunteer for 80 hours a month—and then prove it. The requirements are the most stringent Republicans have ever put forward. Most of the coverage losses would be from people who are eligible but aren't able to meet the reporting requirements. Under pressure from conservatives, GOP leaders amended an initial version of the bill to enact the changes by the end of 2026 at the latest, a timeframe that experts and advocates warn will lead to rushed implementation by states and even more people losing insurance. Outside of Medicaid, the legislation also would codify into law some technical and controversial changes President Trump proposed to make to the Affordable Care Act. Among other changes, the bill would end automatic reenrollment in ACA plans for people getting subsidies, end certain special enrollment periods, and shorten the overall open enrollment. According to CBO, the ACA changes would result in 3 million additional uninsured people. Senate Republicans have already indicated changes are possible regarding some of the proposed reforms to the Supplemental Nutrition Assistance Program (SNAP) crafted in the House. The bill would require states to cover a share of SNAP benefits costs, which are currently completely funded by the federal government. The bill would lower the federal share of the cost of SNAP from 100 percent to 95 percent starting fiscal 2028. The bill also includes language that would increase states' shares of the costs in fiscal 2028 depending on their payment error rates – a move that proponents say would hold states accountable for billions of dollars in erroneous payments to participants annually. If the error rate is 6 percent or higher, states would be subject to a sliding scale that could see their share of allotments rise to a range of between 15 percent and 25 percent. Democrats have sharply criticized the proposal, which they argue could lead to states cutting benefits on their own. In fiscal 2023, data from the U.S. Department of Agriculture showed that the national payment error rate was 11.68 percent. Most states on the list have payment error rates, which factors in a state's overpayments and underpayments, above 6 percent. Other proposals in the bill would beef up work requirements for the program, seek to block the federal government from being able to increase monthly benefits in the future, and increase states' share of costs to administer SNAP. The legislation guts massive subsidies for climate-friendly energy sources, including wind and solar power. Doing so is expected to have significant ramifications on not only the nation's greenhouse gas emissions but also energy prices. A recent analysis from BloombergNEF said that a repeal of the green tax credits would result in 17 percent less renewable construction. It said that the cut, combined with growing electricity demand, is 'a recipe for spiking power prices.' Ethan Zindler, policies and countries analyst with BloombergNEF, said that for analysis purposes, the changes made in the House bill are akin to a full repeal. 'The tax code at the moment helps to reduce the cost of electricity for consumers from renewables, which today account for the vast majority of what gets added to the grid,' he said. 'if you remove those supports, then developers will simply seek to charge more, and in a number of cases, utilities will be forced to pay more, and those costs will flow through to consumers.' Several analyses estimate that electric bills could rise noticeably as a result. A Rhodium Group estimate has found that keeping the tax credits in place could save consumers 2 to 4 percent on their electric bills in 2030 and 2 to 5 percent in 2035. Aurora Energy Research has found that removing the tax credits will increase electric bills by an average of 10 percent – or $142 per year – by 2040. While the House bill has a long way to go before it becomes law, it's already sending shockwaves through financial markets. Bond traders have sent U.S. interesting rates rising as the House advanced a bill that most budget scorekeepers project to add at least $4 trillion to the debt over the next decade. This could trickle through to the housing market and credit markets, adding another economic squeeze into the mix. 'Everybody I've talked to in the financial markets, they're staring at the bill, and they thought it was going to be much more in terms of fiscal restraint, and they're not necessarily seeing it,' Federal Reserve Governor Christopher Waller said in an interview last week on Fox Business Network's 'Mornings with Maria.' 'Therefore, there's going to be a lot of issuance of Treasuries. And in order for them to buy these things, they want it at a lower price, and therefore, a higher yield,' he said. Some House fiscal hawks held their noses and voted for the measure despite their concerns, but several GOP senators have already pledged to vote against the bill given its bond market impact. 'I think we're having trouble selling our long bonds already,' warned Sen. Rick Scott (R-Fla.), who cited the rising interest rates. 'I want to get a deal done; I support the president's agenda. I support the border, I support the military, I support extending the Trump tax cuts — but we have to live in reality. But we got to live in reality here: We got a fiscal crisis,' Scott said.
Yahoo
22-05-2025
- Yahoo
TRiCares presents promising First-In-Human Topaz data at EuroPCR 2025
Early results demonstrate near-complete elimination of tricuspid regurgitation in implanted patients with favorable safety profile and no permanent pacemaker implantations Paris, France and Munich, Germany, 22 May, 2025 – TRiCares SAS ('TRiCares'), a privately held pioneer in the field of minimally invasive treatment of tricuspid regurgitation, is presenting data in a late-breaking session at EuroPCR today from its first-in-human trial of Topaz, its Transcatheter Tricuspid Valve Replacement (TTVR) system. Today, Dr Julien Dreyfus, MD, PhD will present 30-day post-procedural data from 20 tricuspid regurgitation (TR) patients treated with Topaz across eight specialist cardiac centers in Europe. The TRICURE First-In-Human study demonstrated significant elimination of TR in treated patients, with grade 'none' (0+) or 'mild' (1+) TR reported in all patients implanted with Topaz. In addition, zero permanent pacemakers were required due to the investigational device. The implantation procedure lasted, on average, 35 minutes. These early clinical results from Topaz compare favorably with existing TTVR treatment approaches, with a procedure that is fast, easy-to-use, and less demanding of imaging specialists. Further details on the data will be shared in today's oral presentation at EuroPCR 2025 and on 'We are highly encouraged by the results of this first-in-human trial. These initial findings serve as important validation for our ongoing clinical trials for Topaz in Europe and the US,' said Ahmed Elmouelhi, President & CEO of TRiCares. 'I want to extend our sincere gratitude to the participating hospitals, the dedicated interventional teams and clinical investigators who contributed to these patient outcomes. To date, the TRiCares team has overseen 60 Topaz implantations, and we continue to work closely with clinicians to refine the procedure and technique.' The initial findings will be used to inform the company's ongoing European pivotal trial (NCT06581471) and U.S. Early Feasibility Study (NCT06506942). EuroPCR presentation details Session: Tricuspid hotline: new devices Title: TRiCares Topaz transfemoral TRICUspid heart valve REplacement system first-in-human trial Presenter: Julien Dreyfus, MD, PhD, FESC, Cardiologist at Centre Cardiologique du Nord, Saint-Denis, France Location: Theatre Bordeaux Date/time: Thursday, 22 May 2025, 08:30 – 09:30 CEST About TRiCaresTRiCares is a privately held company developing Topaz, a minimally invasive tricuspid valve replacement system for the elimination of tricuspid regurgitation (TR). Topaz's unique dual stent design is easy to implant and uses established transfemoral and transjugular delivery methods, avoiding the need for high-risk open-heart surgery. Topaz is designed to fit a wide range of anatomies and replaces the diseased tricuspid valve. Once in place, it flexes with every heartbeat. A European Pivotal Study and a US/Canadian Early Feasibility Study are underway, with progress being made towards FDA approval and CE marking. TRiCares has focused on TR since its inception and its ambition is for Topaz to become the valve of choice for the millions of TR patients worldwide, overcoming the limitations of current treatment approaches. TRiCares is a global business, with offices in France, Germany, the US and Brazil, and is supported by a strategic partner and leading life science venture capital firms: 415 Capital, Andera Partners, Bayern Kapital, BioMed Partners, Credit Mutuel Innovation, GoCapital, Karista, and Wellington Partners. About TopazThe Topaz Transcatheter Tricuspid Valve Replacement (TTVR) System is designed to eliminate tricuspid regurgitation through a minimally invasive approach. This system consists of the Topaz Heart Valve Prosthesis and a catheter-based implantation system. It is developed exclusively for use in the tricuspid position and to provide a system for physicians that is safe and easy to implant. The unique two-stent valve prosthesis is inserted primarily via the femoral vein and transports the prosthesis into the right side of the heart, where it is finally released to replace the diseased tricuspid valve. For further information please contact: TRiCares SASAhmed Elmouelhi, President & CEOinfo@ ICR Healthcare Lucy FeatherstoneT: +44 (0)20 3709 5700tricares@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
